The abstract is read at the publisher; the summary is JClub's.
High-risk CCUS patients (n=409) defined by CHRS or CCRS show clinical features and event rates comparable to lower-risk MDS (n=241), despite morphology-based uncertainty.
- Why it matters: Morphology thresholds make it hard to distinguish CCUS from lower-risk MDS, even though they overlap clinically and molecularly and differ in progression risk.
- What they did: In a prospective cohort of 409 CCUS and 241 LR-MDS patients, investigators used harmonized diagnostic/progression criteria, centralized pathology review, and uniform genomic profiling, stratifying risk with CHRS and CCRS.
- The result: Low- or intermediate-risk CCUS had markedly improved outcomes, while a subset of high-risk CCUS converged clinically and genomically with LR-MDS, supporting risk-adapted management and trial enrollment.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.